Events

Participate in a moderated discussion with Richard Scheller, Chief Science Officer and head of the newly formed therapeutics group. In his role, Dr. Scheller is responsible for building a dedicated research and development team that will use human genetic data as the starting point for identifying new therapies for both common and rare diseases. Dr. Scheller will share his experiences and activities at 23andMe, as well as his time as EVP of R&D at Genentech.